Life Edit Therapeutics
Tian Yang is currently a Scientist I in Protein Engineering at Life Edit Therapeutics since September 2023. Prior to this role, Tian served as a Doctoral Student Researcher at Duke University Pratt School of Engineering from August 2018 to August 2023, where research focused on developing multiagent screening for directed evolution and served as a Teaching Assistant for BME590L Biotech Design. Earlier experience includes research assistant positions at Tsinghua University, contributing to synthetic biology projects involving CRISPR-Cas tools, medical image deep learning for breast cancer diagnosis, and metabolic engineering of Corynebacterium glutamicum. Tian holds a Doctor of Philosophy in Biomedical Engineering from Duke University and a Bachelor of Science in Chemistry & Biology from Tsinghua University, along with a minor in Journalism & Communications.
Life Edit Therapeutics
Life Edit, an ElevateBio company, is a next-generation genome editing company that has built a highly innovative platform with one of the world’s largest and most diverse collections of novel RNA-guided nucleases (RGNs) and base editors. The platform allows Life Edit to target any genomic sequence and develop novel human therapeutics for the most challenging genetic diseases by enabling ex vivo engineering for cell therapies and regenerative medicines and in vivo delivery of gene therapies. In addition to developing its own pipeline of cell and gene therapies, Life Edit Therapeutics will continue to strengthen its platform of genome-editing enzymes, provide gene-editing expertise to strategic partners, and form other third-party partnerships to discover and develop new therapies.